Experimental drug aims to reverse liver scarring in NASH cirrhosis
NCT ID NCT05039450
First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time
Summary
This phase 2b trial tests whether efruxifermin, an experimental drug, can improve liver fibrosis (scarring) without worsening inflammation in people with compensated cirrhosis due to NASH. Participants receive either efruxifermin or a placebo for up to 96 weeks. The main goal is to see if more people on the drug achieve at least a one-stage reduction in fibrosis compared to placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental drug called efruxifermin
- What this could lead to
- If successful, this could point toward a treatment that reverses liver scarring in people with advanced NASH cirrhosis, potentially preventing the need for a liver transplant.
- What could go wrong
- This is an early-phase trial with a modest number of participants, so results may not confirm benefit. The drug may cause side effects or fail to improve fibrosis in a larger population.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASH - NONALCOHOLIC STEATOHEPATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Akero Clinical Study Site
Chandler, Arizona, 85224, United States
-
Akero Clinical Study Site
Glendale, Arizona, 85306, United States
-
Akero Clinical Study Site
Tucson, Arizona, 85711, United States
-
Akero Clinical Study Site
Tucson, Arizona, 85712, United States
-
Akero Clinical Study Site
North Little Rock, Arkansas, 72117, United States
-
Akero Clinical Study Site
Fresno, California, 93720, United States
-
Akero Clinical Study Site
Long Beach, California, 90808, United States
-
Akero Clinical Study Site
Los Angeles, California, 90036, United States
-
Akero Clinical Study Site
Pasadena, California, 91105, United States
-
Akero Clinical Study Site
Englewood, Colorado, 80113, United States
-
Akero Clinical Study Site
Clearwater, Florida, 33761, United States
-
Akero Clinical Study Site
Fort Myers, Florida, 33907, United States
-
Akero Clinical Study Site
Fort Myers, Florida, 33912, United States
-
Akero Clinical Study Site
Hialeah Gardens, Florida, 33016, United States
-
Akero Clinical Study Site
Lakewood Rch, Florida, 34211, United States
-
Akero Clinical Study Site
Miami Lakes, Florida, 33016, United States
-
Akero Clinical Study Site
Ocala, Florida, 34471, United States
-
Akero Clinical Study Site
Sarasota, Florida, 34240, United States
-
Akero Clinical Study Site
South Bend, Indiana, 46635, United States
-
Akero Clinical Study Site
Topeka, Kansas, 66606, United States
-
Akero Clinical Study Site
Bastrop, Louisiana, 71220, United States
-
Akero Clinical Study Site
Marrero, Louisiana, 70072, United States
-
Akero Clinical Study Site
Las Vegas, Nevada, 89109, United States
-
Akero Clinical Study Site
Concord, North Carolina, 28027, United States
-
Akero Clinical Study Site
Fayetteville, North Carolina, 28304, United States
-
Akero Clinical Study Site
Morehead City, North Carolina, 28557, United States
-
Akero Clinical Study Site
Springboro, Ohio, 45066, United States
-
Akero Clinical Study Site
Westlake, Ohio, 44145, United States
-
Akero Clinical Study Site
Greenville, South Carolina, 29605, United States
-
Akero Clinical Study Site
Greenwood, South Carolina, 29646, United States
-
Akero Clinical Study Site
Summerville, South Carolina, 29485, United States
-
Akero Clinical Study Site
Nashville, Tennessee, 37211, United States
-
Akero Clinical Study Site
Austin, Texas, 78746, United States
-
Akero Clinical Study Site
Dallas, Texas, 75246, United States
-
Akero Clinical Study Site
Edinburg, Texas, 78504, United States
-
Akero Clinical Study Site
Edinburg, Texas, 78539, United States
-
Akero Clinical Study Site
Fort Worth, Texas, 75044, United States
-
Akero Clinical Study Site
Fort Worth, Texas, 76104, United States
-
Akero Clinical Study Site
Houston, Texas, 77030, United States
-
Akero Clinical Study Site
Houston, Texas, 77079, United States
-
Akero Clinical Study Site
San Antonio, Texas, 78215, United States
-
Akero Clinical Study Site
Waco, Texas, 76710, United States
-
Akero Clinical Study Site
Webster, Texas, 77598, United States
-
Akero Clinical Study Site
Wichita Falls, Texas, 76301, United States
-
Akero Clinical Study Site
Ogden, Utah, 84405, United States
-
Akero Clinical Study Site
Richmond, Virginia, 23298, United States
-
Akero Clinical Study Site
Mexico City, Mexico
-
Akero Clinical Study Site
Monterrey, Mexico
-
Akero Clinical Study Site
San Juan, 00927, Puerto Rico
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug HPG1860 shows promise in reducing liver fat in NASH patients
- Hope for NASH: new pill aims to reverse liver damage and prevent cirrhosis
- Sleeve gastrectomy vs. lifestyle: which tames fatty liver disease?
- Can a keto diet help obese patients with advanced liver disease?
- New MRI scan could predict liver cancer in NASH patients
- Can Weight-Loss surgery reverse severe fatty liver disease?